Recent Updates
Recently added Catalysts
GSK Neutral Sentiment

Transfer of Treasury Shares

Key Takeaway: On November 20, 2026, GSK plc transferred 22 million ordinary shares to JPMorgan Chase Bank for the issuance of 11 million American depositary receipts. This move was to satisfy awards under the company's Deferred Annual Bonus Plan and other incentive plans. After the transfer, GSK holds 248,881,064 ordinary shares in treasury.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
Belimumab
Phase 3 · Lung Diseases, Interstitial

Full Press Release Details

On 20 November 2026, GSK plc (the “Company”) transferred 22,000,000 ordinary shares of 31¼ pence each (“Ordinary Shares”) that were held by the Company in treasury (“Treasury Shares”) to JPMorgan Chase Bank, N.A., the depositary of the Company’s American depositary receipts (“ADR”) programme, to procure the issuance and transfer of 11,000,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the “Trust”), to be used to satisfy awards granted under the Company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of the Trust, of $47.82 per ADR, representing $23.91 per Ordinary Share, was funded by a contribution to the Trust from GlaxoSmithKline LLC.
Following the transfer, the Company will hold 248,881,064 Ordinary Shares in treasury and have 4,067,451,066 Ordinary Shares in issue (excluding Treasury Shares).
The total number of voting rights in the Company is 4,067,451,066. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company confirms that, in accordance with DTR 5.5.1R, following the above transfer the percentage of voting rights attributable to the Treasury Shares is 6.12%.
This announcement is made in accordance with the requirements of UK Listing Rule 9.8.2.
Notifications may be sent to company.secretary@gsk.com.
V A Whyte
Company Secretary
20 November 2026
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG

Frequently Asked Questions

How many shares did GSK transfer?

GSK transferred 22,000,000 ordinary shares to JPMorgan Chase Bank.

Why were the shares transferred?

To issue 11,000,000 ADRs for employee bonus and share plans.

How many shares remain in treasury?

GSK holds 248,881,064 ordinary shares in treasury after the transfer.

What is the total voting rights count?

Total voting rights are 4,067,451,066 following the transfer.

Last updated: Nov 20, 2026